PRAC Recommends Marketing Authorization of Ulipristal Acetate be Revoked

News
Article

PRAC has recommended the marketing authorization of ulipristal acetate for the treatment of uterine fibroids be revoked.

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has issued its recommendation to revoke the marketing authorization of 5-mg ulipristal acetate (Esmya and generic medicines) for the treatment of uterine fibroids.

According to a Sept. 4, 2020 press release, PRAC has confirmed that ulipristal acetate can cause liver injury after considering all available evidence, including reported cases of serious liver injury. During the review, patient and healthcare professional representatives were also consulted.

As it has not been possible to identify patients that are more at risk of liver injury, including serious liver injury, that would enable the risk to be reduced of using the medicine, PRAC has concluded that 5-mg ulipristal acetate should not be marketed in the European Union. The use of the medicines had already been suspended while the review was being performed.

PRAC’s recommendation will now be forwarded to EMA’s Committee for Medicinal Products for Human Use (CHMP).

Source: EMA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes